文献速递流行病学与生物统计

英国新冠疫苗随机对照试验的包容性如何:一项调查黑人成人与少数族裔成人入组的系统综述

How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities.
PubMed 文献 · Trials · 2024-04-12

该研究依据PRISMA指南系统综述英国新冠疫苗随机对照试验,比较黑人成人和少数族裔成人的入组比例与2011年人口普查数据。共纳入7篇论文、87组来自英国试验点的数据。黑人成人平均入组比例为0.59%(95%CI:0.13%–1.05%),显著低于人口普查的2.67%(p<0.001);少数族裔成人平均入组比例为8.94%(95%CI:2.07%–15.80%),低于普查的16.30%(p=0.039)。结论认为试验未能按比例充分随机入组这两类人群,需发展并实施更具包容性的招募实践。

要点

  • 黑人成人平均入组比例为0.59%(95%CI:0.13%–1.05%),显著低于普查的2.67%(p<0.001)。
  • 少数族裔成人平均入组比例为8.94%(95%CI:2.07%–15.80%),低于普查的16.30%(p=0.039)。
  • 作者认为新冠疫苗试验未能充分随机入组黑人和少数族裔成人,需发展并实施更具包容性的招募实践。

核心结论

  • 新冠疫苗试验未能按比例充分随机入组黑人成人和少数族裔成人。
  • 作者认为需在服务不足群体的招募中发展并实施更具包容性的实践,以理解新冠的真实影响。

研究设计与样本

  • 系统综述,遵循PRISMA指南,检索英国开展的新冠疫苗随机对照试验。
  • 检索词包括MeSH词「Covid-19 vaccine」「Ad26COVS1」「BNT162 Vaccine」及关键词covishield、coronavac、Vaxzevria、NVX-CoV2373等。
  • 纳入标准为提供参与者人口学资料和完整入选标准的研究。
  • 最终纳入7篇论文,汇总来自英国各试验点的87组数据。
  • 主要结局为被判定符合纳入标准的新冠疫苗试验中黑人成人随机入组的平均百分比,次要结局为少数族裔成人随机入组的平均百分比。

主要发现

  • 黑人成人入组平均百分比为0.59%(95%CI:0.13%–1.05%),显著低于记录的成年黑人人口比例2.67%(p<0.001)。
  • 少数族裔成人入组平均百分比为8.94%(95%CI:2.07%–15.80%),低于人口普查数据16.30%(p=0.039)。

关键数值与推荐

  • 黑人成人入组比例0.59%(95%CI:0.13%–1.05%)vs 人口普查2.67%,p<0.001。
  • 少数族裔成人入组比例8.94%(95%CI:2.07%–15.80%)vs 人口普查16.30%,p=0.039。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To establish if Black adults and adult ethnic minorities, defined as any group except White British, were represented in UK-based COVID-19 vaccination randomised controlled trials (RCTs) when compared to corresponding UK population proportions, based on 2011 census data. DESIGN: Systematic review of COVID-19 Randomised Controlled Vaccine Trials SETTING: United Kingdom PARTICIPANTS: Randomised Controlled Trials of COVID-19 vaccines conducted in the UK were systematically reviewed following PRISMA guidelines. MeSH terms included "Covid-19 vaccine", "Ad26COVS1", and "BNT162 Vaccine" with keywords such as [covishield OR coronavac OR Vaxzevria OR NVX-CoV2373] also used. Studies that provided (A) participant demographics and (B) full eligibility criteria were included. The following key data was extracted for analysis: number of participants analysed, number of Black adults and number of adult minority ethnicity participants. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome is the mean percentage of Black adults randomised to COVID-19 vaccine trials deemed eligible within this review. The secondary outcome is the mean percentage of adult ethnic minorities randomised. RESULTS: The final review included 7 papers and a total of 87 sets of data collated from trial sites across the UK. The standard mean percentage of Black adults included in the trials (0.59%, 95% CI: 0.13% - 1.05%) was significantly lower compared to the recorded Black adult population (2.67%) indicating that they were under-served in UK based COVID-19 vaccine RCTs (p < 0.001). Adult ethnic minority presence (8.94%, 95% CI: 2.07% - 15.80%) was also lower than census data (16.30%), indicating they were also under-served (p = 0.039). CONCLUSION: The findings show that COVID-19 vaccine trials failed to adequately randomise proportionate numbers of Black adults and adult minority ethnicities. More inclusive practices must be developed and implemented in the recruitment of underserved groups to understand the true impact of COVID-19.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Herieka H, Babalis D, Tzala E, et al. How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities. Trials. 2024. PMID: 38605411. doi:10.1186/s13063-024-08054-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。